Oprelvekin: an alternative treatment for thrombocytopenia.
Oprelvekin (Neumega, Genetic Institute Co., Cambridge, MA) is a thrombopoietic growth factor approved by the U.S. Food and Drug Administration for the prevention of severe thrombocytopenia following myelosuppressive chemotherapy in patients with nonmyeloid malignancies. The most common side effects are edema, dyspnea, tachycardia, and conjunctival redness. Patient-care concerns include appropriate timing of administration, patient selection, dosing and administration issues, and the early identification and management of side effects.
Rust
D M
DM
Wood
L S
LS
Battiato
L A
LA
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017370:Interleukin-11 / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010347:Patient Care Planning; D010353:Patient Education as Topic; D018579:Patient Selection; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000628:therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D017370:Interleukin-11; D011994:Recombinant Proteins; C105308:oprelvekin